In October, AstraZeneca revealed that early results from a phase 3 trial of its dual-drug asthma inhaler Airsupra were so convincing that an independent committee decided to halt the study based ...

The study found that Airsupra, its dual-action asthma rescue inhaler, led to meaningful improvements in patients with mild asthma compared to albuterol alone. AIRSUPRA is the only FDA-approved ...

AstraZeneca (AZ) has shared positive results from a phase 3b study of its anti-inflammatory reliever rescue therapy Airsupra ...

Albuterol/budesonide is a short-acting beta2-agonist (SABA) and inhaled corticosteroid (ICS) asthma rescue therapy approved under the brand name Airsupra ®. The product is indicated for as-needed ...

The results from the AIRSUPRA BATURA trial add to a wide body of evidence on the value of the anti-inflammatory reliever rescue approach to not only provide immediate relief from symptoms ...

Airsupra (albuterol and budesonide) is a brand-name inhaler that doctors may prescribe to treat asthma in adults. It does not have a generic version. Medicare Part D prescription drug plans may ...

The BATURA trial demonstrated treatment with Airsupra significantly reduced the risk of a severe exacerbation by 47% when compared with albuterol alone, Astra said in a statement.

Doctors prescribe Airsupra (albuterol and budesonide) to treat asthma in adults. There’s no generic version of the medication. If you have a Medicare Part D drug plan, Medicare may cover the ...

The BATURA trial, which compared as-needed AIRSUPRA against the commonly used as-needed albuterol, demonstrated a 47% reduction in the risk of a severe exacerbation for those treated with AIRSUPRA.

Positive full results from the BATURA Phase IIIb trial showed AstraZeneca’s anti-inflammatory reliever rescue therapy, AIRSUPRA (albuterol/budesonide), demonstrated statistically significant and ...